Death to the Primary Care Blockbuster? What 2007 Says About the Future of the Drug Industry
This article was originally published in RPM Report
Executive Summary
The pharmaceutical industry just had its worst year of growth since 1961, and it doesn't look like there are enough primary care blockbuster launches in 2008 to turn those numbers around. The big lesson from 2007: specialty care is increasingly where pharma needs to be.
You may also be interested in...
Enject's GlucaPen: Mightier than the Hypo-kit?
Decades after recombinant insulin first hit the market insulin is still big business. But in the race to lock up that market, the big players haven't done much to address a key problem with treating high blood sugar with insulin--a better way to inject the hormone glucagon when blood sugar levels drop way too low, or hypoglycemia. Enter Enject. The start-up has amassed exclusive worldwide commercial licenses to several pieces of technology that have enabled it to develop an auto-injector pen similar to the EpiPen, which is used to administer epinephrine in the event of severe allergic reactions. Enject hopes it can parlay its nifty device into a lucrative business development deal with one of the big insulin drug or device players.
Enject's GlucaPen: Mightier than the Hypo-kit?
Decades after recombinant insulin first hit the market insulin is still big business. But in the race to lock up that market, the big players haven't done much to address a key problem with treating high blood sugar with insulin--a better way to inject the hormone glucagon when blood sugar levels drop way too low, or hypoglycemia. Enter Enject. The start-up has amassed exclusive worldwide commercial licenses to several pieces of technology that have enabled it to develop an auto-injector pen similar to the EpiPen, which is used to administer epinephrine in the event of severe allergic reactions. Enject hopes it can parlay its nifty device into a lucrative business development deal with one of the big insulin drug or device players.
Enject's GlucaPen: Mightier than the Hypo-kit?
Decades after recombinant insulin first hit the market insulin is still big business. But in the race to lock up that market, the big players haven't done much to address a key problem with treating high blood sugar with insulin--a better way to inject the hormone glucagon when blood sugar levels drop way too low, or hypoglycemia. Enter Enject. The start-up has amassed exclusive worldwide commercial licenses to several pieces of technology that have enabled it to develop an auto-injector pen similar to the EpiPen, which is used to administer epinephrine in the event of severe allergic reactions. Enject hopes it can parlay its nifty device into a lucrative business development deal with one of the big insulin drug or device players.